Filing Flows › Beam Therapeutics (BEAM) › Q3 2026 › vs Q3 2025
Beam Therapeutics (BEAM) Q3 2026 vs Q3 2025 (year over year)
Beam Therapeutics's revenue fell $9.4M (-97%) from $9.7M in Q3 2025 to $307K in Q3 2026.
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $307K | $9.7M | −$9.4M | -97% |
| Other income, net | $6.9M | $14.1M | −$7.2M | -51% |
| Net loss | $134M | $113M | $21.8M | +19% |
| Costs & expenses | $142M | $136M | $5.3M | +4% |
| Operating costs | $142M | $137M | $5.1M | +4% |
| Research & development | $110M | $110M | $341K | +0.3% |
| General & admin | $31.5M | $26.7M | $4.8M | +18% |
| Operating cash sources | $135M | $110M | $25.0M | +23% |
| Depreciation | $5.4M | $5.6M | −$115K | -2% |
| Share-based compensation | $18.6M | $22.7M | −$4.2M | -18% |
| Cash used in operations | $111M | $81.5M | $29.3M | +36% |
| Net loss absorbed | $134M | $113M | $21.8M | +19% |
| Working capital & other | $343K | −$2.8M | $3.1M | — |
Questions
How much did Beam Therapeutics's revenue grow year over year in Q3 2026?
Beam Therapeutics's revenue fell $9.4M (-97%) from $9.7M in Q3 2025 to $307K in Q3 2026.